Nuclera, the biotechnology company accelerating drug discovery by providing rapid, easy access to functional proteins through its benchtop eProtein Discovery™ System, has signed a partnership with Solve Scientific Australia, a life science research solutions provider.
The agreement is the latest milestone in UK-based Nuclera’s global expansion, broadening access to eProtein Discovery to customers in Australia and New Zealand, and amplifying the Company’s presence in key Asian and Pacific markets.
The Asia Pacific recombinant protein market is rapidly growing and is anticipated to reach a projected revenue of $ 1,455 million by 2030 (CAGR of 11.7%). This partnership recognizes the need to support this growth and will enable drug discovery researchers in Australia and New Zealand with streamlined access to eProtein Discovery, following expansion across APAC and the Middle East earlier this year. This agreement will provide localized support and expertise to existing and new customers in these regions.
Applying digital microfluidics alongside in situ protein detection assays and cell-free protein synthesis, eProtein Discovery significantly reduces time and cost of protein production by automating construct screening, protein scale-up, and producing purified proteins for downstream functional testing in under 48 hours. The system accelerates workflows, achieving results in days rather than the months required by traditional cell-based methods.
